2023 World Conference on Lung Cancer (Posters)-EP12.01. A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib

EP12.01. A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib - PDF(Slides)

Back to course

Pdf Summary

A case study from China reported the successful treatment of a lung adenocarcinoma patient with co-mutations of MET Exon 14 Skipping and EGFR exon 21 L858R using Aumolertinib. The patient, a 47-year-old male, had been diagnosed with right lung adenocarcinoma accompanied by mediastinal lymph nodes and brain metastases. The patient received antivascular drugs combined with chemotherapy followed by Aumolertinib therapy. The treatment resulted in sustained remission of intracranial lesions and partial response in lung and intracranial masses. Polymerase chain reaction (PCR) detection confirmed the presence of both EGFR exon 21 L858R and MET exon14 skipping mutations. The patient continued to show positive response with shrinking of the lung and intracranial masses, as well as the disappearance of metastatic lesions in the left frontal lobe. The patient's progression-free survival (PFS) exceeded 18 months on Aumolertinib monotherapy. There were no significant drug-related adverse events during the treatment period. This case study represents the first report of Aumolertinib's use in patients with co-mutations of EGFR and MET, providing a potential treatment option for such patients. Ongoing clinical trials are evaluating the combination of Aumolertinib with a c-MET inhibitor for the treatment of advanced non-small cell lung cancer (NSCLC), with the aim of providing further treatment options in the future.

Asset Subtitle

Yan Chen

Meta Tag

Speaker Yan Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

China

case study

lung adenocarcinoma

MET Exon 14 Skipping

EGFR exon 21 L858R

Aumolertinib

patient

chemotherapy

intracranial lesions

progression-free survival